Navigation Links
Intestinal enzyme helps maintain population of beneficial bacteria
Date:10/18/2010

An enzyme that keeps intestinal bacteria out of the bloodstream may also play an important role in maintaining the normal microbial population of the gastrointestinal system. Since the loss of beneficial bacteria that usually results from antibiotic therapy can sometimes lead to serious health problems, a treatment that maintains microbial levels could have significant benefits.

"Our mouse studies confirmed that giving this enzyme by mouth keeps the gut healthy, in terms of the microbes that usually live there," says Richard Hodin, MD, of the Massachusetts General Hospital (MGH) Department of Surgery, senior author of the report in the November issue of the journal Gut. "This could prevent infection with dangerous bacteria like Salmonella and C. difficile, which can occur when the normal bacterial population becomes depleted, and may lead to development of a supplement to maintain intestinal health whenever someone takes an antibiotic."

Virtually all higher animals maintain a population of microbes primarily bacteria in their digestive tracts. These organisms are not only harmless, they also benefit their host by helping with digestion, and their presence prevents the more pathogenic bacteria that may be present from proliferating. Because antibiotics kill all non-resistant bacteria, including those residing in the intestines, the usual balance of beneficial versus harmful microbes is destroyed, leading to problems ranging from diarrhea to infections with dangerous antibiotic-resistant organisms.

A 2008 study by members of Hodin's team that investigated why intestinal bacteria and their toxins do not pass into the bloodstream found that intestinal alkaline phosphatase (IAP), an enzyme produced by the intestinal lining, blocks the activity of a toxic molecule found on many pathogenic bacteria. Because that study and findings by other groups showed that IAP acts against several bacterial toxins, the MGH researchers looked at whether the enzyme directly interacted with intestinal bacteria.

Studies of mice lacking the gene for IAP revealed that the animals had reduced levels of all intestinal bacteria and practically none of the common beneficial strains of E. coli. In fact, the most common E. coli strain would not grow if introduced into these knockout mice. But when the animals received oral doses of IAP, beneficial E. coli proliferated quickly after other microbial species were killed by antibiotics. Experiments with normal mice infected with an antibiotic-resistant Salmonella strain showed that IAP treatment significantly reduced Salmonella levels in the animals' feces. Although only 20 percent of animals not treated with IAP survived, 70 percent of those receiving the enzyme were alive 7 days later.

"We believe that IAP rapidly restores E. coli and other beneficial bacteria after antibiotic treatment and that the higher numbers of these bacteria prevent colonization by Salmonella or other pathogens by competing for nutrients and attachment sites," says Mahdu Malo, PhD, MBBS, of MGH Surgery, corresponding and first author of the Gut paper. "We need to test this approach in larger animals before planning a human clinical trial, but this approach has the potential of solving a common, often serious health problem."


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Protein Appears Key to Intestinal Balance
2. ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
3. Feedback loop explains inflammatory effect on intestinal lining
4. A new endoscopic technique for gastrointestinal perforations: the over-the-scope-clip
5. Factors increasing the risk of atrophic gastritis and intestinal metaplasia
6. The effect of dietary supplements, acids and animal protein on gastrointestinal disorders
7. Suppressing activity of common intestinal bacteria reduces tumor growth
8. Motorcycle Cancer Risk and ELF EMF Radiation Invasion of Gastrointestinal Melatonin
9. What affects the gastrointestinal symptoms in peritoneal dialysis patients?
10. Optimal surgical procedure for duodenal gastrointestinal stromal tumors
11. New studies highlight obesitys impact on gastrointestinal health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... WASHINGTON D.C. (PRWEB) , ... July 25, 2017 ... ... therapists and their clients, today announced it will be exhibiting and providing demos ... Convention at the Walter E. Washington Convention Center in Washington D.C. from August ...
(Date:7/25/2017)... ... July 25, 2017 , ... USHEALTH Group, Inc. has ... prestigious CEO World Awards®. The coveted annual CEO World Awards program encompasses the ... studies, corporate social responsibility, and milestones from every major industry in the world. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... SignatureCare ... scholarship will be awarded for the fall semester to a deserving student. Get ... Centers Spring 2017 scholarship was awarded to Mariana Castillo who is a nursing student ...
(Date:7/24/2017)... Peru (PRWEB) , ... July 24, 2017 , ... ... for $1,000 total in scholarship awards to be awarded annually to and divided ... demonstrate an interest in bringing awareness to Amazonian plant medicine. To apply for ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... two organizations that already work hand-in-hand on an Innovation Collaboration program, have signed ... access, quality, experience and cost of the care members and patients receive. The ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
(Date:7/11/2017)... -- Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe and ... painful intercourse and other painful pelvic pain conditions such as pelvic floor ... ... ... -based start-up company, VuVatech LLC, fills a void in the women,s ...
(Date:7/10/2017)...  The tenth annual BioPharm America™ will ... at the Sheraton Boston Hotel, September 26–27. The event ... decision makers and innovative biotech startup companies. The event ... two impactful days. BioPharm America is now part of ... opportunities with 4,500+ life science industry influencers participating in ...
Breaking Medicine Technology: